GlaxoSmithKline News and Research

RSS

GSK decides to remove potentially hazardous zinc from denture adhesive products

GlaxoSmithKline, the maker of popular denture adhesives Poligrip and Super Poligrip, announced today that it will remove zinc from all of its denture adhesive products. The pharmaceutical giant has added the potentially hazardous mineral to its adhesives for decades, despite overwhelming evidence that consuming large quantities of zinc over an extended period of time can cause serious neurological damage.

19 Feb 2010

New report shows dramatic rise in medical technology, pharmaceuticals and healthcare costs

Management of Emerging Healthcare Solutions, Inc. (Pinksheets: EHSI) stated that they were encouraged by a new report that parallels the company’s conclusions about the new potential for business in the current healthcare marketplace.

19 Feb 2010

FDA's proposed label changes for LABA asthma medications: GSK reviews

GlaxoSmithKline is reviewing label changes proposed today by the US Food and Drug Administration (FDA) for asthma medications containing long-acting beta-agonists (LABAs), such as GSK's Advair (salmeterol / fluticasone propionate). GSK and makers of the other affected medicines containing LABAs have 30 days to agree with the proposed changes or state why they are not warranted.

19 Feb 2010

Asthma: LABAs should not be used alone

The U.S. Food and Drug Administration today announced that drugs in the class of long-acting beta agonists (LABAs) should never be used alone in the treatment of asthma in children or adults. Manufacturers will be required to include this warning in the product labels of these drugs, along with taking other steps to reduce the overall use of these medications.

19 Feb 2010

Antigenics announces fourth-quarter and full-year 2009 financial results

Antigenics Inc. reported today its results for the quarter and year ended December 31, 2009. The company reported net income attributable to common stockholders of $1.7 million, or $0.02 per share, basic and diluted, for the fourth quarter of 2009, compared with net income attributable to common stockholders in the fourth quarter of 2008 of $3.9 million, or $0.06 per share, basic and diluted.

18 Feb 2010

GSK Consumer Healthcare applauds two smoking cessation organizations for improving smoking cessation aids

GlaxoSmithKline Consumer Healthcare, marketer of nicotine replacement therapy (NRT) products, including Nicorette®, NicoDerm® CQ® and Commit®, applauds two leading smoking cessation organizations for their efforts to improve the regulation of smoking cessation aids designed to help people quit smoking.

18 Feb 2010

FDA issues Complete Response Letter for Horizant in treatment of RLS

GlaxoSmithKline and XenoPort, Inc. Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).

18 Feb 2010

AAFA launches national PSA on "Two Main Causes of Asthma"

The Asthma and Allergy Foundation of America (AAFA) is launching a national public service announcement (PSA) supported by GlaxoSmithKline titled "Two Main Causes of Asthma." The PSA goal is to communicate an important message to the millions of Americans with asthma: that treating the two main causes of asthma symptoms may help prevent symptoms before they begin. Asthma symptoms include coughing, wheezing, difficulty breathing and chest tightness.

17 Feb 2010

Meda publishes 2009 year-end report

“The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009.”

16 Feb 2010

IMPACT Awards acknowledge nonprofit organizations that provide access to healthcare for underserved

The GlaxoSmithKline 14th Annual IMPACT Awards target community-based nonprofits that provide access to healthcare for the underserved. Up to ten organizations in the Pennsylvania counties of Berks, Bucks, Chester, Delaware, Lancaster, Lehigh, Montgomery, and Philadelphia and the City of Camden, New Jersey, will be awarded $40,000 each.

16 Feb 2010

Public health researchers at UNC to lead multi-state initiative to prevent cervical cancer

Asserting that no one should die from cervical cancer, public health researchers at the University of North Carolina at Chapel Hill are leading a multi-state initiative to prevent - or even eradicate - the disease.

16 Feb 2010

EMBL-EBI hosts ChEMBLdb online database

ChEMBLdb, an online database of information on the properties of more than half a million drug and drug-like small molecules and their targets, has been launched.

12 Feb 2010

Simcere Pharmaceutical Group subsidiary receives Chinese SFDA approval for Zanamivir

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that one of its subsidiaries, Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd., has received new drug registration approval from the State Food and Drug Administration ("SFDA") to manufacture and sell Zanamivir, a neuraminidase inhibitor inhalant used in the prevention and treatment of Influenza A and Influenza B. Zanamivir is marketed globally by GlaxoSmithKline under the trade name Relenza.

11 Feb 2010

'CARES by GSK' introduces oncology co-pay assistance program

GlaxoSmithKline today announced the launch of CARES by GSK, a comprehensive program that provides a single point of contact to GSK services and programs designed to improve access to GSK oncology and specialty medications. In addition to the comprehensive offerings that include specialty reimbursement services and free medicine, CARES by GSK now offers its first oncology co-pay assistance program to further help eligible patients with limited insurance coverage to have better access to GSK oral oncology and specialty medicines.

11 Feb 2010

Model Metrics launches Pharma2GO sales force automation solution for pharma and life science industries

Model Metrics has launched Pharma2GO Spring '10, a comprehensive sales force automation solution specifically designed for the pharmaceutical and life science industries that extends the power of Salesforce CRM to mobile devices.

10 Feb 2010

Merck's asthma drug formoterol/mometasone to garner global peak year sales of more than $250M

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, following its expected launch this year for the treatment of asthma, Merck's formoterol/mometasone will garner peak year sales of more than $250 million in the United States, France, Germany, Italy, Spain and the United Kingdom.

9 Feb 2010

GlaxoSmithKline announces reduction in the investment into treatments for pain and depression

GlaxoSmithKline today said it had posted a strong performance in a challenging year with a return to sales growth for the first time since 2007.

5 Feb 2010

Pharma IQ to organize 4th Improving Solubility conference at The Park Hyatt in Philadelphia

Organized by Pharma IQ, a division of IQPC, the 4th Improving Solubility conference will be held March 29-31, 2010 at The Park Hyatt in Philadelphia, PA. This forum brings together pharmaceutical researchers and scientists to uncover advances in enhancing solubility, amorphous forms, bioavailability & lipid-based formulation of drugs.

From IQPC Ltd 5 Feb 2010

Biota Holdings reports Relenza sales, indicative royalties for three months ended 31 December 2009

Biota Holdings Limited today announced that it had received written notification from GlaxoSmithKline that Relenza sales were $462 million and indicative royalties were $32.6 million, for the three months ended 31 December 2009.

5 Feb 2010

Tecan Group, Enigma Diagnostics sign manufacturing and supply agreement for Enigma ML instruments

The Tecan Group, a leading global provider of laboratory instruments and solutions, and Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today the signing of a manufacturing and supply agreement for Enigma's ML instruments.

From Tecan 5 Feb 2010

GlaxoSmithKline News and Research

GSK decides to remove potentially hazardous zinc from denture adhesive products

New report shows dramatic rise in medical technology, pharmaceuticals and healthcare costs

FDA's proposed label changes for LABA asthma medications: GSK reviews

Asthma: LABAs should not be used alone

Antigenics announces fourth-quarter and full-year 2009 financial results

GSK Consumer Healthcare applauds two smoking cessation organizations for improving smoking cessation aids

FDA issues Complete Response Letter for Horizant in treatment of RLS

AAFA launches national PSA on "Two Main Causes of Asthma"

Meda publishes 2009 year-end report

IMPACT Awards acknowledge nonprofit organizations that provide access to healthcare for underserved

Public health researchers at UNC to lead multi-state initiative to prevent cervical cancer

EMBL-EBI hosts ChEMBLdb online database

Simcere Pharmaceutical Group subsidiary receives Chinese SFDA approval for Zanamivir

'CARES by GSK' introduces oncology co-pay assistance program

Model Metrics launches Pharma2GO sales force automation solution for pharma and life science industries

Merck's asthma drug formoterol/mometasone to garner global peak year sales of more than $250M

GlaxoSmithKline announces reduction in the investment into treatments for pain and depression

Pharma IQ to organize 4th Improving Solubility conference at The Park Hyatt in Philadelphia

Biota Holdings reports Relenza sales, indicative royalties for three months ended 31 December 2009

Tecan Group, Enigma Diagnostics sign manufacturing and supply agreement for Enigma ML instruments

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News